Conservation biologist Brian Gratwicke searches with his team for frogs in Altos de Campana National Park in Panama. Nate ...
The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...
Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
Promising results from a new malaria drug offer hope against emerging drug resistance in Africa. In a clinical trial, ...
In what experts are calling a breakthrough in the global fight against malaria, a new next-generation drug candidate — GanLum ...
Every cell of the deadly Plasmodium falciparum parasite, the organism that causes malaria, contains a tiny compartment full of microscopic iron crystals. As long as the parasite is alive, the crystals ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Indian Defence Review on MSN
New Malaria Treatment Could Save Hundreds of Thousands of Lives
A promising new malaria drug shows incredible promise in fighting resistance and could save thousands of lives.
Novartis plans to seek quick regulatory approvals from health authorities for the drug, known as GanLum, which would be the ...
Explore Laveran's groundbreaking discovery of the malaria parasite and its lasting impact on infectious disease research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback